Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors

M Righi, I Gannon, M Robson, S Srivastava… - Cancer Immunology …, 2023 - AACR
Adoptive T-cell therapy aims to achieve lasting tumor clearance, requiring enhanced
engraftment and survival of the immune cells. Cytokines are paramount modulators of T-cell …

A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine …

Y Xu, Z Yang, LH Horan, P Zhang, L Liu, B Zimdahl… - Cell discovery, 2018 - nature.com
The clinical use of genetically modified T-cell therapies has led to unprecedented response
rates in leukemia and lymphoma patients treated with anti-CD19 chimeric antigen receptor …

Augmenting human gamma delta lymphocytes for cancer therapy with chimeric antigen receptors

GM Ferry, J Anderson - Exploration of Immunology, 2022 - discovery.ucl.ac.uk
Gamma delta lymphocytes (γδ T) sit at the interface between innate and adaptive immunity.
They have the capacity to recognize cancer cells by interaction of their surface receptors …

[HTML][HTML] Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells

YC Kuo, CF Kuo, K Jenkins, AFH Hung… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Chimeric antigen receptor (CAR) T cells engineered to recognize and target
tumor associated antigens have made a profound impact on the quality of life for many …

CAR T-cell integration of multiple input signals allows for precise targeting of cancer

D Achkova, M Pule - Cancer Discovery, 2018 - AACR
Chimeric antigen receptor (CAR)–mediated adoptive T-cell therapy has achieved
unprecedented success in the treatment of relapsed and refractory hematologic …

Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy

M Jonnalagadda, A Mardiros, R Urak, X Wang… - Molecular Therapy, 2015 - cell.com
The success of adoptive therapy using chimeric antigen receptor (CAR)–expressing T cells
partly depends on optimal CAR design. CARs frequently incorporate a spacer/linker region …

Generation of anti-tumor chimeric antigen receptors incorporating T cell signaling motifs

L Balagopalan, T Moreno, H Qin, J Yi, KM McIntire… - bioRxiv, 2022 - biorxiv.org
Chimeric antigen receptors (CAR) T cells have been successfully used to treat lymphoma,
leukemia, and multiple myeloma, but adverse effects due to cytokine secretion, CAR-T cell …

Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity

LCS Wang, A Lo, J Scholler, J Sun, RS Majumdar… - Cancer immunology …, 2014 - AACR
The majority of chimeric antigen receptor (CAR) T-cell research has focused on attacking
cancer cells. Here, we show that targeting the tumor-promoting, nontransformed stromal …

Refining chimeric antigen receptors via barcoded protein domain combination pooled screening

X Rios, O Pardias, MA Morales, P Bhattacharya… - Molecular Therapy, 2023 - cell.com
Chimeric antigen receptor (CAR)-T cells represent a promising frontier in cancer
immunotherapy. However, the current process for developing new CAR constructs is time …

Chimeric antigen receptors (CARs) incorporating mutations in the IgG4 Fc spacer region to eliminate Fc receptor recognition results in improved CAR T cell …

M Jonnalagadda, A Mardiros, L Hoffman… - … for immunotherapy of …, 2013 - Springer
Adoptive immunotherapy using T cells genetically redirected via expression of chimeric
antigen receptors (CARs) is a promising approach for cancer treatment. However, this …